CY1108745T1 - Πεπτιδια δια τη θεραπευτικη αγωγη κακης συμπεριφορας μεταξυ προσωπων - Google Patents

Πεπτιδια δια τη θεραπευτικη αγωγη κακης συμπεριφορας μεταξυ προσωπων

Info

Publication number
CY1108745T1
CY1108745T1 CY20091100058T CY091100058T CY1108745T1 CY 1108745 T1 CY1108745 T1 CY 1108745T1 CY 20091100058 T CY20091100058 T CY 20091100058T CY 091100058 T CY091100058 T CY 091100058T CY 1108745 T1 CY1108745 T1 CY 1108745T1
Authority
CY
Cyprus
Prior art keywords
patients
disorders
environment
persons
therapeutic
Prior art date
Application number
CY20091100058T
Other languages
English (en)
Inventor
Tony Marcel
François Rougeon
Catherine Rougeot
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of CY1108745T1 publication Critical patent/CY1108745T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Radiation-Therapy Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Η εφεύρεση αφορά τον τομέα της ψυχοφαρμακολογίας. Ειδικότερα η εφεύρεση αφορά τη θεραπευτική αγωγή παθήσεων DSM-III, και παθήσεων κακής συμπεριφοράς μεταξύ προσώπων, συμπεριλαμβανομένων των σεξουαλικών παθήσεων όπως M.E.D. και H.S.D.D. Η εφεύρεσις προσφέρει νέες θεραπευτικές συνθέσεις και μεθόδους δια τη θεραπευτική αγωγή DSM-II παθήσεων, συμπεριλαμβανομένων των M.E.D. και H.S.D.D. Οι συνθέσεις και οι μέθοδοι συμφώνως προς την εφεύρεση εξασφαλίζουν βελτιωμένη αντίληψη και εγρήγορση προς το περιβάλλον, βελτιωμένη προσαρμογή προς το περιβάλλον και ικανότητα παρατάσεως της προσοχής και αυξημένο ενδιαφέρον προς το περιβάλλον και ικανότητα αφυπνίσεως χωίς αυξημένη επιθετικότητα.
CY20091100058T 1999-06-23 2009-01-16 Πεπτιδια δια τη θεραπευτικη αγωγη κακης συμπεριφορας μεταξυ προσωπων CY1108745T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14056399P 1999-06-23 1999-06-23
EP05006494A EP1593387B1 (en) 1999-06-23 2000-06-22 Compositions for the treatment of impaired interpersonal and behavioral disorders

Publications (1)

Publication Number Publication Date
CY1108745T1 true CY1108745T1 (el) 2014-04-09

Family

ID=22491816

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100058T CY1108745T1 (el) 1999-06-23 2009-01-16 Πεπτιδια δια τη θεραπευτικη αγωγη κακης συμπεριφορας μεταξυ προσωπων

Country Status (14)

Country Link
US (2) US7387778B2 (el)
EP (2) EP1593387B1 (el)
JP (1) JP2003512302A (el)
CN (1) CN1189211C (el)
AT (2) ATE414529T1 (el)
AU (1) AU6154700A (el)
CA (1) CA2376935A1 (el)
CY (1) CY1108745T1 (el)
DE (2) DE60019106T2 (el)
DK (2) DK1185294T3 (el)
ES (2) ES2238299T3 (el)
NZ (1) NZ516477A (el)
PT (2) PT1593387E (el)
WO (1) WO2001000221A2 (el)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
NZ516477A (en) 1999-06-23 2004-02-27 Pasteur Institut Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
EP1216707B1 (en) * 2000-12-22 2005-02-09 Institut Pasteur Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ES2350123T3 (es) 2003-01-28 2011-01-18 Ironwood Pharmaceuticals, Inc. Composiciones para el tratamiento de trastornos gastrointestinales.
EP1577320B1 (en) 2004-03-19 2012-07-18 Institut Pasteur Peptides derived from human BPLP protein, polynucleotides coding for said peptides and antibodies directed against said peptides
ES2393885T7 (es) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA2720778C (en) 2008-04-07 2017-10-17 Institut Pasteur Opiorphin peptide derivatives as potent inhibitors of enkephalin - degrading ectopeptidases
FR2931362B1 (fr) 2008-05-26 2017-08-18 Pasteur Institut L'opiorphine pour une utilisation en tant que psychostimulant.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
CA2645452A1 (en) * 2008-11-28 2010-05-28 Institut Pasteur Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker
US20100221329A1 (en) 2008-12-03 2010-09-02 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
DE102009039655B3 (de) 2009-09-02 2011-03-31 ITT Mfg. Enterprises, Inc., Wilmington UV-Desinfektionseinrichtung für Abwasser und Trinkwasser mit einer Reinigungsvorrichtung
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
JP6251038B2 (ja) 2011-03-01 2017-12-20 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの調製方法
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
GB201607814D0 (en) 2016-05-04 2016-06-15 5D Health Prot Group Ltd Anti-microbial compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8327966D0 (en) * 1983-10-19 1983-11-23 Nyegaard & Co As Chemical compounds
FR2637600B1 (fr) * 1988-10-11 1992-03-06 Pasteur Institut Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques
US5589189A (en) * 1994-09-14 1996-12-31 Nexstar Pharmaceuticals, Inc. Liposome dispersion
US6589750B2 (en) * 1997-02-20 2003-07-08 Institut Pasteur Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives
KR100353014B1 (ko) 1998-11-11 2002-09-18 동아제약 주식회사 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
NZ516477A (en) 1999-06-23 2004-02-27 Pasteur Institut Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders
EP1216707B1 (en) 2000-12-22 2005-02-09 Institut Pasteur Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide

Also Published As

Publication number Publication date
WO2001000221A3 (en) 2001-05-03
PT1185294E (pt) 2005-08-31
DE60040878D1 (de) 2009-01-02
ATE414529T1 (de) 2008-12-15
US7387778B2 (en) 2008-06-17
ATE291927T1 (de) 2005-04-15
JP2003512302A (ja) 2003-04-02
US20030078200A1 (en) 2003-04-24
CN1356906A (zh) 2002-07-03
EP1593387A1 (en) 2005-11-09
US20030186870A1 (en) 2003-10-02
ES2238299T3 (es) 2005-09-01
PT1593387E (pt) 2009-03-18
AU6154700A (en) 2001-01-31
DE60019106D1 (de) 2005-05-04
CA2376935A1 (en) 2001-01-04
DE60019106T2 (de) 2006-02-16
EP1593387B1 (en) 2008-11-19
DK1593387T3 (da) 2009-03-02
CN1189211C (zh) 2005-02-16
EP1185294A2 (en) 2002-03-13
NZ516477A (en) 2004-02-27
DK1185294T3 (da) 2005-08-01
WO2001000221A2 (en) 2001-01-04
EP1185294B1 (en) 2005-03-30
ES2315753T3 (es) 2009-04-01

Similar Documents

Publication Publication Date Title
CY1108745T1 (el) Πεπτιδια δια τη θεραπευτικη αγωγη κακης συμπεριφορας μεταξυ προσωπων
Larrosa et al. Laser-assisted uvulopalatoplasty for snoring: does it meet the expectations?
HRP20020593B1 (en) Brain, spinal and nerve injury treatment
ATE510542T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
WO2003075850A3 (en) Methods for alzheimer's disease treatment and cognitive enhancement
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
ATE123936T1 (de) Mittel mit physiologischem kühleffekt und für diese mittel geeignete wirksame verbindungen.
ATE325612T1 (de) Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen
WO2003014309A3 (en) Interleukin-1 receptors in the treatment of diseases
DE69400799D1 (de) Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen
HUP0102511A2 (hu) Kombinált gyógykezelés bipoláris betegségek kezelésére
ATE477811T1 (de) Oxytocin zur behandlung von autismus und asperger-syndrom
BR0109211A (pt) Compostos com atividade 5-ht1a úteis para o tratamento de distúrbios da retina externa
TNSN06403A1 (en) 3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
WO2005020928A3 (en) Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
ATE359079T1 (de) Verfahren zur behandlung von übelkeit, erbrechen, würgereiz oder jede kombination daraus
Reavis et al. Patterned sound therapy for the treatment of tinnitus
ATE296098T1 (de) Verwendung von topiramat zur behandlung und diagnostizierung von atemstörungen während des schlafens und mittel zur durchführung der behandlung und diagnose
ATE541565T1 (de) Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus
EP1262197A3 (en) Combination treatment for sleep disorders including sleep apnea
EA200501117A1 (ru) Способ лечения снижения когнитивной способности вследствие лишения сна и стресса
WO2004058329A3 (en) Ester combination local anesthetic
HUP0402673A2 (hu) Erekciózavar kezelésére szolgáló prosztaglandin készítmény
PT1000046E (pt) Derivados de piperazina activos no trato urinario inferior
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.